Icosapent ethyl (Vascepa) coverage
Customize your policy alerts
Sign up for Peach State Health Plan Policy CP.PMN.187 alerts
Get alerted when Policy CP.PMN.187 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity, prior authorization, and continuation criteria for icosapent ethyl (Vascepa) for Peach State Health Plan members (HIM/ICHRA, Medicaid). Applies to provider requests for Vascepa coverage under the referenced plan.
Added step therapy bypass for IL HIM per IL HB 5395.
Extended initial approval duration from 6 months to 12 months for this maintenance medication for a chronic condition.
For reduction of CVD risk, reduced statin adherence duration from 4 months to 8 weeks and simplified statin trial/failure criteria.
Added request must not exceed health-plan approved quantity limit for all indications.
For hypertriglyceridemia without ASCVD, added 3 consecutive month trial requirement for failure of omega-3-acid ethyl esters.
Coverage Criteria
Initial Therapy: Hypertriglyceridemia without ASCVD
Covered when ALL of the following are met
Illinois HIM requests: step therapy requirements do not apply per IL HB 5395
Initial Therapy: Reduction of Cardiovascular Disease Risk
Covered when ALL of the following are met
Statin intensity definitions and statin intolerance criteria referenced in appendices
Continuation Therapy: Hypertriglyceridemia without ASCVD
Continued therapy covered when ALL of the following are met
Labs/documentation required to show response
Continuation Therapy: Reduction of Cardiovascular Disease Risk
Continued therapy covered when ALL of the following are met
Labs/documentation required to show response
General / administrative criteria
Coverage tied to indication-specific criteria and prior therapy trials
Product available as 0.5 g and 1 g capsules; see step therapy and statin requirements for indication-specific conditions
CVD risk reduction
Reduction of cardiovascular disease (CVD) risk criteria revisions
Documentation of prior statin therapy duration/response or documented statin intolerance required as specified in policy appendices
Hypertriglyceridemia without ASCVD
Hypertriglyceridemia without ASCVD criteria
IL HIM bypass applies per IL HB 5395 for step therapy requirements
Non–FDA approved indications that are not specifically addressed by this policy are not authorized unless the request is supported by sufficient documentation of efficacy and safety in accordance with the applicable off‑label use policy: HIM.PA.154 (marketplace/ICHRA) or CP.PMN.53 (Medicaid), or by other recognized evidence of coverage documents. Requests for off‑label use should include supporting clinical literature or policy justification per those referenced off‑label policies.
Statin therapy contraindications and important contextual exclusions that affect concomitant statin decisions include: decompensated liver disease (e.g., development of jaundice, ascites, variceal bleeding, encephalopathy); laboratory‑confirmed acute liver injury or rhabdomyolysis resulting from statin treatment; pregnancy, actively trying to become pregnant, or nursing; and immune‑mediated hypersensitivity to the HMG‑CoA reductase inhibitor class (e.g., allergic reaction to at least two different statins). Note: the FDA has requested removal of the strongest pregnancy contraindication for statins (see FDA communication).
This policy has been revised in the 1Q 2026 annual review to reflect administrative and clinical updates: added a step‑therapy bypass for Illinois HIM per IL HB 5395; added a requirement that requests must not exceed the health‑plan approved quantity limit for all indications; extended the initial authorization duration for maintenance therapy from 6 months to 12 months; and for the CVD risk‑reduction indication, reduced the required documented statin adherence period from 4 months to 8 weeks and simplified prior statin‑trial/failure language for moderate/low intensity regimens. Additionally, for hypertriglyceridemia without ASCVD a 3‑consecutive‑month trial requirement for failure of omega‑3‑acid ethyl esters was added.
Clinical Thresholds & Coding Values
Initial Therapy Criteria
Initial Therapy
Initial coverage requires meeting indication-specific criteria and prior therapy/statin requirements where applicable
Requests must not exceed plan-approved quantity limits and dosing must not exceed 4 g/day (4 capsules/day).
Initial therapy
Initial therapy prior-treatment requirements
Documentation of trials required
See appendices for statin intensity definitions and intolerance criteria
Continuation / Maintenance Criteria
Continuation Therapy
Continuation criteria require evidence of prior authorization or current receipt and clinical response
Labs and office documentation must be provided to support response
Continuation therapy
Continuation/maintenance authorization updates
Specific continuation clinical criteria are detailed in indication-specific continuation nodes
Step Therapy Requirements
| Step | Requirement | Applicability / Notes |
|---|---|---|
| 1 | ||
| Failure of ≥3 consecutive months of fibrate therapy at up to maximally indicated doses and failure of ≥3 consecutive months of omega-3‑acid ethyl esters (generic Lovaza) at up to maximally indicated doses prior to approval of icosapent ethyl (Vascepa) | ||
| Required for Hypertriglyceridemia without ASCVD; does not apply to Illinois HIM requests per IL HB 5395; requests must not exceed health‑plan approved quantity limit and dose must not exceed 4 g/day (4 capsules/day) |
| Step | Required prior trial | Applicability / Notes |
|---|---|---|
| 1 | ||
| Trial of omega‑3‑acid ethyl esters (e.g., generic Lovaza) for 3 consecutive months with documented failure or contraindication prior to icosapent ethyl (Vascepa) | ||
| Required for Hypertriglyceridemia without ASCVD; Illinois HIM requests exempt from step therapy per IL HB 5395; policy update added explicit 3‑month trial requirement and notes plan quantity limits and 4 g/day dosing cap |
Provider Actions & Prior Authorization
Submit documentation to support all approval criteria
Prior authorization is required and requests must include documentation demonstrating that the member meets all approval criteria; policy states Vascepa is medically necessary when criteria are met.
- Include clinical evidence that each numbered criterion in the applicable indication (e.g., diagnosis, age, lab values, prior therapy trials, dosing limits) is satisfied.
Follow updated PA rules: IL HIM bypass and 12-month initial approvals
Prior authorization requirements were updated: Illinois HIM (marketplace/ICHRA) requests have a step therapy bypass per IL HB 5395, and initial approvals have been extended to 12 months for maintenance therapy. Ensure the request reflects these updates and does not exceed plan-approved quantity limits.
- If the request is for an Illinois HIM member, step therapy requirements do not apply per IL HB 5395.
- Initial approval duration for maintenance therapy is 12 months (updated from 6 months).
Document ≥3‑month trials of fibrate and Lovaza for HyperTG
For the hypertriglyceridemia without ASCVD indication, prior to approval the member must have failed at least a 3‑month trial of fibrate therapy and a 3‑month trial of omega‑3‑acid ethyl esters (Lovaza) at maximally indicated doses unless contraindicated or adverse effects occurred.
- Fibrate trial: ≥ 3 consecutive months within the last 6 months at maximally indicated doses unless contraindicated or adverse effects.
- Omega‑3‑acid ethyl esters (Lovaza) trial: ≥ 3 consecutive months at maximally indicated doses unless contraindicated or adverse effects.
Require 3‑month Lovaza trial before Vascepa (IL HIM exempt)
Before approving icosapent ethyl for hypertriglyceridemia without ASCVD, document a 3‑consecutive‑month trial and failure of omega‑3‑acid ethyl esters; note Illinois HIM requests are exempt from this step therapy per IL HB 5395.
- Record dates, doses, and reason for failure/contraindication for the omega‑3‑acid ethyl ester trial (minimum 3 months).
- If member is in Illinois HIM, indicate IL HB 5395 bypass to exempt step therapy.
Include office notes, labs, and prior‑therapy records
Provider must submit supporting documentation such as office chart notes, lab results, or other clinical information to verify that the member has met each approval criterion.
- Include fasting triglyceride labs dated within 90 days when required by the indication.
- Provide records of prior medication trials (drug name, dose, duration, and reason for failure or intolerance).
Document statin duration/adherence or statin intolerance
When coverage depends on statin use or intolerance for CVD risk reduction, submit documentation of statin therapy: duration of adherence to maximally tolerated statin (at least 8 weeks) or documentation of statin intolerance (e.g., reversible muscle‑related symptoms associated with both rosuvastatin and atorvastatin) as specified by the policy.
- If on statin therapy, document adherence to maximally tolerated statin regimen for the last 8 weeks.
- If statin intolerance is claimed, provide documentation per the policy’s statin intolerance criteria (e.g., described reversible muscle‑related symptoms or prior high‑intensity trial details).
Insufficient documentation or non‑FDA indications risk denial
Requests lacking documentation that the member met all approval criteria, or requests for non‑FDA indications not addressed by this policy without off‑label evidence, may be denied.
- For non‑FDA uses, include sufficient off‑label evidence or follow HIM.PA.154 / CP.PMN.53 off‑label use policies.
- Ensure all required labs and prior‑therapy records are included to avoid denial for insufficient documentation.
Ensure request does not exceed plan quantity or dose limits
Requests that exceed the health‑plan approved quantity limit or dose limits (greater than 4 g/day or more than 4 capsules/day) may be denied; ensure the request does not exceed the plan‑approved quantity limit.
- Verify request quantity against the plan‑approved quantity limit.
- Dose must not exceed 4 g per day and 4 capsules per day.
Quantity Limits & Product
Background
Icosapent ethyl (Vascepa) is the ethyl ester of eicosapentaenoic acid (EPA). The FDA‑labeled indications referenced in this policy include use as an adjunct to maximally tolerated statin therapy to reduce the risk of major cardiovascular events in adults with elevated triglycerides (≥150 mg/dL) with established cardiovascular disease or diabetes plus additional risk factors, and as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia (≥500 mg/dL). Dosing for labeled indications is typically 2 g orally twice daily (total 4 g/day); plan quantity limits apply and initial approvals have been set to 12 months per the policy updates.
Definitions
Site of Care
No site‑of‑care restrictions specified
No site‑of‑care restrictions are specified for this policy in the cited document chunks.
Revision History
1Q 2026 annual review: added step therapy bypass for IL HIM per IL HB 5395; added requirement that requests not exceed health-plan approved quantity limit; extended initial approval duration from 6 months to 12 months; for CVD risk reduction, reduced required statin adherence duration from 4 months to 8 weeks and simplified statin trial/failure criteria for moderate- and low-intensity regimens.
Per 2026 guideline updates: updated language related to hypertriglyceridemia without ASCVD and atorvastatin references; references reviewed and updated.
Added ICHRA line of business and updated references; clarified LDL goals by indication and updated statin requirement language.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.